Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06600516 · ClinicalTrials.gov registry record · NA

Assessing Modified CBTi in Adults with Insomnia Disorder

A NA study of Insomnia Disorder and Cognitive Functioning, sponsored by Idaho State University.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06600516 is a NA study of Insomnia Disorder and Cognitive Functioning that is actively recruiting participants, run by Idaho State University. The registered enrollment target is 40 participants, below the 470-participant average among 8 other Insomnia Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06600516, a NA study of Insomnia Disorder and Cognitive Functioning, is actively recruiting participants, sponsored by Idaho State University.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Sleep is a biological need, crucial for maintaining overall health and resiliency. Sleep disorders disrupt this normal functioning. Insomnia disorder is the most prevalent sleep disorder and yields costs to the U.S. Healthcare System in billions of dollars per year. Chronic insomnia has been linked to numerous physical and psychological health outcomes as well as increased mortality. There is also evidence that insomnia is a risk factor for worse inflammation, worse neurological functioning, cognitive performance, and mild cognitive impairment, including cognitive decline, Alzheimer's disease, and faster genetic and brain aging. Moreover, in patients with Alzheimer's disease those with insomnia showed a faster progression to dementia. Better sleep health provides neuroprotection against this decline. Impairment in objective and subjective cognitive performance, highlights the utility of treating insomnia to potentially improve cognitive outcomes during midlife and insomnia symptoms are a modifiable risk factor for cognitive decline, mild cognitive impairment, and Alzheimer's disease and related dementia. Cognitive Behavioral Therapy for Insomnia (CBTi) is the gold-standard, first line recommended treatment for insomnia, and has considerably better long-term outcomes than medications. CBTi decreases insomnia symptom severity by 50%. CBTi also appears to improve cognitive functioning. However, CBTi is underutilized, training is limited, and medical professionals are implementing treatment approaches inconsistent with empirically supported guidelines. Insomnia symptoms are being inadequately treated while misinformation and misconceptions about insomnia disorder, CBTi, and actual therapeutic effects are being propagated. Moreover, sedating medications are currently the most commonly used treatment for insomnia, which is problematic because the potential side effects can have major implications for the aging population. Additionally, some patients continue to experien

Interventions

  • BEHAVIORAL CBTi: Stimulus Control Core
  • BEHAVIORAL CBTi: Sleep Restriction Core
  • BEHAVIORAL CBTi: Sleep Compression Core

Study Locations (1)

Idaho

  • Idaho State University Psychology Clinic - Pocatello

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-09-06
Est. Completion 2025-06
Phase NA

Sponsor

Idaho State University

8 total trials

What the Registry Record Tells You About NCT06600516

The ClinicalTrials.gov registry entry for NCT06600516 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 8 other Insomnia Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Idaho State University, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Insomnia Disorder appearing as the primary indexed condition, and to 3 interventions - of which CBTi: Stimulus Control Core is the first listed.

NCT06600516 reports 1 study location spanning 1 distinct geographic area - top geographies include Idaho.

Frequently Asked Questions

What is clinical trial NCT06600516 about?

NCT06600516 is a clinical study titled "Assessing Modified CBTi in Adults with Insomnia Disorder". Sleep is a biological need, crucial for maintaining overall health and resiliency. Sleep disorders disrupt this normal functioning. Insomnia disorder is the most prevalent sleep disorder and yields costs to the U.S. Healthcare System in billions of dollars per year. Chronic insomnia has been linked ...

What is the current status of trial NCT06600516?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-09-06. Estimated completion is 2025-06.

What conditions does trial NCT06600516 study?

This clinical trial studies the following conditions: Insomnia Disorder, Cognitive Functioning.

What interventions are being tested in trial NCT06600516?

The interventions under investigation include: CBTi: Stimulus Control Core (BEHAVIORAL), CBTi: Sleep Restriction Core (BEHAVIORAL), CBTi: Sleep Compression Core (BEHAVIORAL).

Who is sponsoring clinical trial NCT06600516?

This trial is sponsored by Idaho State University, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06600516 being conducted?

This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.